Geert Kersten

@ThomasJurman Danke

@GeertKersten1 Dear Mr Kersten, please find an interesting article about EMA published from DerStandard / Austria (German language) derstandard.at/story/30000002… Best regards Thomas Jurman

Most investments begin in discomfort. That is what a famous investor wrote. oaktreecapital.com/insights/memo/…. We are at that stage because until a few days ago there was no clear regulatory path to market. Now there is. Look at our clinical data. Think longer term for huge returns. $CVM

$CVM Thank you for the go-ahead from FDA for the confirmatory trial. We already know how the selected patients did in the completed study. 73% survival with Multikine vs 45% without Multikine. We can help a lot of patients. I believe! So I bought more stock.

@PavelKounine Meetings are followed by official minutes. Announcements should only be made based on the official minutes.

$CVM At CEL-SCI we are looking forward to a month filled with several very important meetings designed to bring our cancer therapy Multikine to market. We will keep you updated on our progress.

$CVM If I look at our history, things have always taken longer than hoped for, but we were always successful in the end. These results make it clear that our Multikine can really help cancer patients. That is the key, helping cancer patients.

$CVM If I was a head and neck cancer patient, I surely would want to get the chance to have my expected death rate reduced from 54 to 22%. Nothing else has worked for these patients in ages.

CEL-SCI $CVM Corporation Issues Letter to Shareholders #Multikine - businesswire.com/news/home/2022…

$CVM We persisted when experts told us that cancer immunotherapy would not work, that head & neck cancer was an impossible to treat disease, yet we have an almost 4 yr survival benefit for patients receiving our Multikine plus surgery and radiation.

$CVM We had well over 100 interested physicians review the results of our Phase 3 head and neck cancer study with us today at ASCO 2022. Very positive feed back. Thank you Dr. Talor.

$CVM I am so proud of our team. An almost 4 year survival benefit in head and neck cancer with no toxicity added. That is why we believe!

@tvdb26 That is so true. If this was an easy business we would have eliminated cancer a long time ago. Data, data, data!

@GeertKersten1 “One of the things you learn fighting cancer is never give up. If something’s important, you keep fighting This is a company that kept fighting.” Quote from Jonathan Sessler from Pharmacyclics ;).

$CVM When you finally learn the details of the huge data set for the Multikine Phase 3 study, think of how this might help cancer patients. That is what will drive things from here on. The rest is background noise.

@biggercapital Dr. Talor and I will be there. It should be exciting.

Next few weeks will be nuts … who’s coming to ASCO?

$CVM It is a sad statement for our society when a Company has to defend itself from stock manipulators after creating a novel cancer drug that increases survival from 48 to 62% at 5 yrs with no safety issues, beating all statistics. Unmet medical need, orphan drug status.

$CVM We showed survival data exceeding all primary endpoints for 1 of 2 treatment arms with no safety issues. On the call yesterday we showed that this analysis was pre-specified in the protocol and conducted BEFORE unblinding, confirmed by the biostatistician, per the FDA rules

$CVM FDA works on the basis of data and clinical benefit. They will decide whether a statistically significant 5 yr. survival difference between 48 and 62% for a terrible unmet need is approvable. Does it help these patients? We believe that it does.

@mastervp The details of the $CVM study will end up being published in one or more peer reviewed scientific publications. We cannot announce the details because that would preclude publication in the top journals. This is how data is typically disseminated.

$CVM Such amount of misinformation. Great data and we believe very approvable. The analysis we did was included in the protocol and the Statistical Analysis Plan and is therefore acceptable to FDA. The group is 1 of 2 and represents over 150,000 patients.

$CVM I tip my hat in respect of the short sellers ability to make the great survival benefit with no safety issues look bad. Unreal. This reminds me of when we won the arbitration against Inventiv, a huge win, and the stock declined. I bought over 300,000 shares at $0.84.